News
News Center
![[Science and Technology Daily] Stem cell research could spark a revolution in medical technology](https://omo-oss-image.thefastimg.com/portal-saas/pg2024091209142318355/cms/image/ca716faf-6406-4d84-a280-c55d825e77a3.png "[Science and Technology Daily] Stem cell research could spark a revolution in medical technology")
2023-08-07
[Science and Technology Daily] Stem cell research could spark a revolution in medical technology
In recent years, rapidly advancing technologies such as spatial omics, single-cell spatiotemporal genomics sequencing, single-molecule techniques, ultra-sensitive proteomics analysis, and proximity labeling approaches have significantly propelled stem cell research, providing the technological foundation needed to achieve functional organ reconstruction.
+
2023-07-26
The main content of this guideline is divided into four sections: an overview, key considerations for communication, important notes, and examples. This guideline applies to communication regarding cell and gene therapy products based on clinical trial protocols.
+
2023-07-20
Recently, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereafter referred to as "Jiuzhitang Maker") received inspection reports from the China Institute of Food and Drug Control (hereafter referred to as "CIFDC"), confirming that human bone marrow mesenchymal stem cell products sourced from different donors and produced in various batches all met the required quality standards.
+
2023-07-20
Recently, according to the relevant provisions of the "Management Measures for the Construction and Operation of Key Laboratories in Hunan Province" (Hunan Science and Technology Development [2022] No. 173), 22 key laboratories in Hunan Province have been officially announced following procedures including organizational recommendations, expert consultations, and committee reviews. Among them is the "Hunan Provincial Key Laboratory for Critical Quality Attributes of Cell Therapy Products," which Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.—the stem-cell pharmaceutical enterprise under Jiuzhitang—has helped establish.
+
2023-07-20
Jiuzhitang Maker's latest stem-cell drug has received IND approval for clinical trials!
On June 9, 2023, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as "Jiuzhitang Maker") received implicit approval from the National Medical Products Administration for its Investigational New Drug (IND) application—specifically, for the "Human Bone Marrow Mesenchymal Stem Cell Injection"—for clinical trials targeting autoimmune alveolar proteinosis (aPAP). This marks the first-ever IND submission in China exploring stem cell therapy for aPAP, offering promising new hope for patients suffering from this debilitating condition.
+
2023-07-20
Stem Cell Science Comic (5) | Stem Cells Reversing Aging
Original science popularization article on stem cells!
+
2023-07-18
Stem Cell Science Comic (4) | The Homing Effect
Original science popularization article on stem cells!
+
2023-05-17
Stem Cell Science Comic (Part 3) | Stem Cell Classification, Sources, and Functions
Original science popularization article on stem cells!
+
2023-04-24
Stem Cell Science Comic (Part 2) | Classification of Cell Therapies (Original)
Original science popularization article on stem cells!
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy